VIVUS Inc

VIVUS — Proxy Contest (July 2013)

43 slides from VIVUS's proxy contest presentation, Jul 3, 2013

  1. Slide 1: Realizing the Value of Vivus

    FIRST MANHATTAN CO. R ealizing the Value of Vivus June 25, 2013

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements FIRST MANHATTAN CO. 2 FIRST MANHATTAN CO. AND/OR ITS AFFILIATES (COLLECTIVELY, “FIRST MANHATTAN”) DO NOT ASSUME RESPONSIBILITY FOR INVESTMENT DECISIONS. THIS PRESENTATION DOES NOT RECOMMEND THE PURCHASE OR SALE OF ANY SECURITY. UNDER NO CIRCUMSTANCES IS THIS PRESENTATION

  3. Slide 3: Additional Information

    Additional Information FIRST MANHATTAN CO., FIRST HEALTH, L.P., FIRST HEALTH LIMITED, FIRST HEALTH ASSOCIATES, L.P., FIRST BIOMED MANAGEMENT ASSOCIATES, LLC, FIRST BIOMED, L.P. AND FIRST BIOMED PORTFOLIO, L.P. (COLLECTIVELY, “ FIRST MANHATTAN ”) FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE

  4. Slide 4: About First Manhattan Co.

    About First Manhattan Co. • First Manhattan Co. (FMC) is the largest shareholder of VIVUS, Inc. and currently owns 9,989,604 shares or 9.9% of the Company – an investment worth approximately $ 139 million 1 • We are long - term investors in high - quality assets, and our interests are fully aligned

  5. Slide 5: Why FMC is Seeking Change at Vivus

    Why FMC is Seeking Change at Vivus • FMC first invested in Vivus in 2008 because we saw the enormous potential of Qsymia, the most effective weight loss agent ever developed. • Over the past five years, we have continued to purchase the stock as evidence continues to mount about Qsymia’s effectivene

  6. Slide 6: FMC's Investment Thesis – The Upside Potential of Qsymia is Enormous

    FMC’s Investment Thesis – The Upside Potential of Qsymia is Enormous • The potential obesity market is huge and growing – Approximately 125 million obese adults in the US and EU • Sanofi - Aventis, Merck and Pfizer all saw blockbuster potential in a class of obesity products that were half as effect

  7. Slide 7: Why a Total Change of the Vivus Board is Required

    Why a Total Change of the Vivus Board is Required FIRST MANHATTAN CO. 7 We believe the Vivus Board: 1. Destroyed Vivus stockholder value with their poor business judgment. The six core members comprise the MAJORITY of the “new and improved” Vivus Board and in our view this MAJORITY is a high risk fo

  8. Slide 8: Why a Total Change of the Vivus Board is Required

    Why a Total Change of the Vivus Board is Required FIRST MANHATTAN CO. 8 • Joined the Board on April 18, 2012. • Coincidentally, on April 25, 2012, seven days after Mr. Mario joined the Board, the Compensation Committee of Vivus approved a new equity compensation arrangement for its non - employee di

  9. Slide 9: Why a Total Change of the Vivus Board is Required

    Why a Total Change of the Vivus Board is Required • FMC has taken an activist approach toward Vivus only as a last resort – There is a clear and achievable path to change that can unlock value for all shareholders • We believe there is an enormous disconnect between the value of Qsymia and its faile

  10. Slide 10: The Vivus Board Lacks Critical Expertise

    1. The Vivus Board Lacks Critical Expertise In our view, the Vivus Board has lacked and still lacks the skill set needed to guide a commercial stage obesity company • Vivus’ Board is led by a long - standing CEO and is composed primarily of legacy Board members who we believe lack the independence,

  11. Slide 11: The Vivus Board is Overpaid

    2. The Vivus Board is Overpaid The Board is enriching itself at shareholders’ expense FIRST MANHATTAN CO. 11 • Vivus non - employee Directors receive more in cash retainers (over $100,000 annually) than non - employee Directors at 4 out of the 5 largest US companies by market cap: Apple ($50,000), G

  12. Slide 12: The Vivus Board is Not Aligned with Shareholders' Interests

    ~ $25 million $0 Value of Vivus shares SOLD by Vivus’ Board members when stock was in the $ 20s Value of Vivus shares PURCHASED by Vivus’ Board members when stock was in the $10s after the Qsymia launch failure 1 Actions speak louder than words: 3. The Vivus Board is Not Aligned with Shareholders ’

  13. Slide 13: The Vivus Board has Mismanaged the Qsymia Launch

    1 FierceBiotech “Analysts rank the top 10 blockbuster duds in biopharma” (April 10, 2013) 4 . The Vivus Board has Mismanaged the Qsymia Launch FIRST MANHATTAN CO. 13 • Qsymia has been ranked as one of the top ten blockbuster DUDS in biopharma history 1 • Case Study #1: Commercial Market Incompetence

  14. Slide 14: The Vivus Board Rewards Failure and is Overly Represented by Management

    NO ACCOUNTABILITY NO ALIGNMENT WITH SHAREHOLDERS’ INTERESTS NO PAY FOR PERFORMANCE 5 . The Vivus Board Rewards Failure and is Overly Represented by Management Year - Over - Year % Change 2012 Cash Bonus 2011 Cash Bonus John Slebir - VP, Business Development and General Counsel 95.4% $183,081 $93,713

  15. Slide 15: Massive Spending With No Return

    Massive Spending With No Return • Look closely: Q4’12A + Q1’13A, SG&A is approximately $95 million but revenues were only $6 million for these six months Undisciplined Capital Allocation Vivus Board has squandered valuable time, money and human resources on Stendra, an erectile dysfunction drug with

  16. Slide 16: The Vivus Board and Management Lack Transparency

    • Management blocks weekly and monthly prescription data from investors, which is highly unusual for a company of this profile • No revenue guidance – short - term or long - term – Consensus revenue estimates for FY13 have plummeted from $201 million to $45 million, and may drop further 1 • Despite

  17. Slide 17: A Number of Research Analysts Agree Change is Necessary at Vivus

    A Number of Research Analysts Agree Change is Necessary at Vivus We believe many in the sell - side research community share our views on the future prospects of Vivus and its challenges*: • Cowen & Co. (4 - 26 - 13) “Our thesis on VVUS continues to be that in order for Qsymia to become a blockbuste

  18. Slide 18: Vivus Board and Management Will Say Anything to Keep Their High-Paying Positions

    In our view, Vivus Board and Management Will Say Anything to Keep Their High - Paying Positions FIRST MANHATTAN CO. 18 Vivus Management Will Tell You: But the Truth Is: • Dramatic change will be disruptive • The deteriorating status quo is exactly what needs to be disrupted • We believe Vivus’ best

  19. Slide 19: Reconstitute the Vivus Board with Nine Independent Nominees

    First Manhattan is asking Vivus shareholders to reconstitute the Vivus Board with nine highly qualified and independent Nominees. FIRST MANHATTAN CO. 19

  20. Slide 20: Our Nominees Have Been Carefully Chosen for Their Skills and Experience

    Our Nominees Have Been Carefully Chosen for Their Skills and Experience Nominee Successful Turnaround Experience Transaction Experience: Partnering, Co - marketing, Licensing and Company/Asset sales New Product Launch Regulatory Financial Has bought/Will Buy VVUS on Election Michael Astrue x x x x x

  21. Slide 21: The Plan to Fix Vivus

    The Plan to Fix Vivus FIRST MANHATTAN CO. 21

  22. Slide 22: Our Nominees Have a Carefully Constructed Strategic Plan

    Our Nominees Have a Carefully Constructed Strategic Plan to Realize Vivus’ Potential 1 1. Ensure the right management is in place 2. Engage the right pharmaceutical partner on the right partnership terms 3. Fix the unsustainable expense structure that is failing to generate revenue 4. Fix the U.S. c

  23. Slide 23: Ensure the Right Management is in Place

    Ensure the Right Management is in Place Problem: Long - standing CEO and senior management lack critical expertise and experience to successfully commercialize Qsymia • We are in advanced discussions with several senior executives to step in as CEO on Day One – We have hired one of the top biopharma

  24. Slide 24: Engage the Right Pharmaceutical Partner on the Right Partnership Terms

    Engage the Right Pharmaceutical Partner on the Right Partnership Terms Problem: Lack of foresight to engage a pharmaceutical partner to sell Qsymia. We believe the current effort to find a partner, which was initiated several weeks ago in response to the proxy contest, is frenzied and could result i

  25. Slide 25: Fix the Unsustainable Expense Structure that is Failing to Generate Revenue

    Fix the Unsustainable Expense Structure that is Failing to Generate Revenue FIRST MANHATTAN CO. 25 The Plan to Fix Vivus Costs are poised to increase even further in Q4 ‘13 - Look at management’s plan for cardiovascular outcomes trial expense of $10 - 15 million and unspecified costly direct - to -

  26. Slide 26: Fix the Unsustainable Expense Structure (cont'd)

    Fix the Unsustainable Expense Structure that is Failing to Generate Revenue (cont’d) • Vivus is hemorrhaging cash at an alarming rate – It is unsustainable and needs to be fixed quickly – The solution is signing a partnership that is 3+ years overdue and cutting expenses significantly • Cut spending

  27. Slide 27: Fix the U.S. Commercial Strategy

    Fix the U.S. Commercial Strategy Problem: Broken U.S. commercial strategy ignores patients’ sensitivity to out - of - pocket expenditures • Follow the best practices of pharma marketing: Lower patients’ out - of - pocket costs to drive utilization • Create customized strategies for different segment

  28. Slide 28: Fix the U.S. Commercial Strategy (cont'd)

    Fix the U.S. Commercial Strategy (cont’d) • Target Physician groups who treat obese patients – Example: Psychiatrists are already comfortable prescribing Topiramate and therefore will likely be comfortable prescribing Qsymia • 67% of obese patients suffer from depression or depressive symptoms – Exa

  29. Slide 29: Optimize Reimbursement Strategy – Medicare and Commercial

    Optimize Reimbursement Strategy – Medicare and Commercial Problem: Vivus has a simplistic and inadequate plan for Medicare reimbursement • Our goal is to make Qsymia the standard of care for all public and private reimbursers – New Board would bring multi - faceted plan with sense of urgency • Aggre

  30. Slide 30: Execute a Euro-Centric Approach to Obtaining E.U. Approval

    Execute a Euro - Centric Approach to Obtaining E.U. Approval Through Centralized Procedure Problem: A seriously flawed approach to E.U. approval for Qsymia that has impaired Vivus’ credibility with European regulators and seriously jeopardizes the substantial value that can be generated in Europe •

  31. Slide 31: Euro-Centric Approach to E.U. Approval (cont'd)

    Execute a Euro - Centric Approach to Obtaining E.U. Approval Through Centralized Procedure (cont’d) • Reconnect Vivus to the European regulators with European experts who have intimate knowledge of the regulators and the regulatory process – Director nominees Drs. John Kastelein and Rolf Bass are hi

  32. Slide 32: Euro-Centric Approach to E.U. Approval (cont'd)

    Execute a Euro - Centric Approach to Obtaining E.U. Approval Through Centralized Procedure (cont’d) • Front - load cardiovascular outcomes trial in Europe 1 (similar to Orexigen) to get E.U. approval at earliest possible date – Primary outcome measure : Non - inferiority (safety) of Qsymia versus pl

  33. Slide 33: Appendix

    Appendix FIRST MANHATTAN CO. 33

  34. Slide 34: First Manhattan Co. Nominees' Biographies

    First Manhattan Co. Nominees’ Biographies FIRST MANHATTAN CO. 34

  35. Slide 35: Nominee Qualifications: Michael Astrue

    Our Nominees are Accomplished and Highly Qualified Nominee Summary of Qualifications Michael Astrue Biography Mr. Astrue most recently served as Commissioner of the Social Security Administration from 2007 to 2013, and was one of six Trustees of the Medicare & Social Security Trust Funds. He was rec

  36. Slide 36: Nominee Qualifications: Dr. Rolf Bass

    Our Nominees are Accomplished and Highly Qualified Nominee Summary of Qualifications Dr. Rolf Bass Biography From 1995 to 2000, Dr. Bass was Head of the Human Medicines Evaluation Unit at the European Medicines Agency (previously, the EMEA) (“the EMA”) in London. He was responsible for the developme

  37. Slide 37: Nominee Qualifications: Jon Biro

    Our Nominees are Accomplished and Highly Qualified Nominee Summary of Qualifications Jon Biro Biography Mr. Biro currently serves as Executive Vice President and Chief Financial Officer at Consolidated Graphics, Inc. (NYSE: CGX), a leading commercial printing services company. Prior to Consolidated

  38. Slide 38: Nominee Qualifications: Dr. Samuel Colin

    Nominee Summary of Qualifications Dr. Samuel Colin Biography Dr. Colin is a Senior Managing Director at First Manhattan Co. (FMC), an investment firm founded in 1964 with more than $14 billion in assets currently under management. Dr. Colin joined the firm in 1994, and is the founding and sole portf

  39. Slide 39: Nominee Qualifications: Dr. Alex Denner

    Nominee Summary of Qualifications Dr. Alex Denner Biography Dr. Denner founded Sarissa Capital Management LP, a registered investment advisor, in 2012. Sarissa Capital focuses on enhancing shareholder value of portfolio companies. From 2006 to November 2011, Dr. Denner served as a Senior Managing Di

  40. Slide 40: Nominee Qualifications: Dr. John Kastelein

    Nominee Summary of Qualifications Dr. John Kastelein Biography Dr. Kastelein has spent his career of more than 30 years devoted to the study of medical genetics, lipidology and molecular biology. He is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the

  41. Slide 41: Nominee Qualifications: Melvin Keating

    Nominee Summary of Qualifications Melvin Keating Biography Since November 2008, Mr. Keating has been a private consultant, providing investment advice and other services to private equity firms. Mr. Keating served as the President and Chief Executive Officer of Alliance Semiconductor Corp., a worldw

  42. Slide 42: Nominee Qualifications: David Norton

    Nominee Summary of Qualifications David Norton Biography Mr. Norton served in a variety of senior leadership positions during his more than 32 - year career at Johnson & Johnson (NYSE: JNJ), most recently as Company Group Chairman, Global Pharmaceuticals from 2009 until his retirement from the compa

  43. Slide 43: Nominee Qualifications: Herman Rosenman

    Nominee Summary of Qualifications Herman Rosenman Biography Mr. Rosenman was most recently at Gen - Probe Inc., a medical diagnostics company, where starting in 2001 he held the role of SVP of Finance and Chief Financial Officer. At Gen - Probe, he led a company spin - off and helped lead Gen - Prob

Vivus — Proxy Contest (July 2013) on 6ix